Ustekinumab
NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)contractFind a Tender ↗Ref ocds-h6vhtk-05f601Procurement Act 2023SME suitablepending
Estimated value
—
Awarded value
£6.5m
Awarded 03 Jun 2026
Suppliers
6
Lots
1
1 awarded
Published
15 Jun 2026
Description
Supply of Ustekinumab
Scope
- Reference
- PHA-FTS-61334
- Commercial tool
- Standalone contract
- Contract dates
- 30 Sept 2026 to 30 Jun 2028Possible extension to 30 Jun 2029
12 month extension option available.
- CPV classifications
- 33600000
- Contract locations
- Wales, United Kingdom
- Particular suitability
- Small and medium-sized enterprises (SME)
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Product quality/acceptability | — | quality | 1.00% |
| Financial (overall cost of contract) | — | price | 2.00% |
| Environmental/Social Value/Community Benefits | — | quality | 3.00% |
Submission & procedure
- Procedure
- Open procedure
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£6.5m
Award date
03 Jun 2026
Contract start
30 Sept 2026
Contract end
30 Jun 2028
Awarded to
Awarded suppliers· 6 suppliers
Awarded 03 Jun 2026 · Contract period 30 Sept 2026 — 30 Jun 2028
Award value
£6.5m
Other contracts from NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)
Full notice and award history for this contracting authority is on the buyer profile.
Other contracts awarded to Amgen Ltd· 10
Cross-buyer view of this supplier's public-sector wins.
| Title | Type | Value | Published |
|---|---|---|---|
| NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 | contract | — | 09 Jun 2026 |
| Transitional Drugs 7 | contract | — | 05 Jun 2026 |
| Transitional Drugs 6 | contract | — | 30 Mar 2026 |
| Transitional Drugs 6 | contract | — | 04 Feb 2026 |
| NP49425 Generic and Biosimilar Transition Medicines | contract | — | 19 Dec 2025 |
| NHS National Framework for Denosumab Injection commencing 1st January 2026 | contract | — | 04 Dec 2025 |
| Project/Contract NHS National Framework for Denosumab Injection | contract | — | 02 Oct 2025 |
| Romiplostim (Nplate®) | contract | — | 10 Sept 2025 |
| NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | contract | £47.0m | 29 Jul 2025 |
| NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025 | contract | — | 29 Jul 2025 |